Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Closed 04-16 16:00:00 EDT

42.24

-1.21

-2.78%

盘后42.24

+0.000.00%

17:17 EDT

High43.48	Low41.52	Vol931.67K
Open43.41	D1 Closing43.45	Amplitude4.51%
Mkt Cap3.03B	Tradable Cap2.12B	Total Shares71.71M
T/O39.22M	T/O Rate1.86%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":42.24,"timestamp":1776369600000,"preClose":43.45,"halted":0,"volume":931670,"hourTrading":{"tag":"盘后","latestPrice":42.24,"preClose":42.24,"latestTime":"17:17 EDT","volume":14497,"amount":612353.63,"timestamp":1776374270426,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0278481012658228,"floatShares":50198200,"shares":71713905,"eps":-4.664443,"marketStatus":"Closed","change":-1.21,"latestTime":"04-16 16:00:00 EDT","open":43.41,"high":43.48,"low":41.52,"amount":39220355.46944,"amplitude":0.045109,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.664443,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":5,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":43.45,"preHourTrading":{"tag":"盘前","latestPrice":43.45,"preClose":43.45,"latestTime":"09:11 EDT","volume":207,"amount":9037.168740000001,"timestamp":1776345112614,"change":0,"changeRate":0,"amplitude":0.021634},"postHourTrading":{"tag":"盘后","latestPrice":42.24,"preClose":42.24,"latestTime":"17:17 EDT","volume":14497,"amount":612353.63,"timestamp":1776374270426,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.558482,"impliedVol":0.8235,"impliedVolPercentile":0.532},"requestUrl":"/m/hq/s/VERA/wiki","defaultTab":"wiki","newsList":[{"id":"2627585792","title":"Vera CEO Marshall Fordyce disposes of Vera Therapeutics shares worth $1,018,054","url":"https://stock-news.laohu8.com/highlight/detail?id=2627585792","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627585792?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:58","pubTimestamp":1776286698,"startTime":"0","endTime":"0","summary":"Vera Therapeutics President and CEO Marshall Fordyce sold 22,951 Class A common shares on April 14, 2026.Sales prices ranged from USD 43.25 to USD 45.67 per share.Fordyce held 235,244 Class A common shares directly following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL1kPYbt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera CEO Marshall Fordyce disposes of Vera Therapeutics shares worth $1,018,054","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4139","BK4585","VERA","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148623","title":"BRIEF-Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148623","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148623?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:31","pubTimestamp":1775853063,"startTime":"0","endTime":"0","summary":"BRIEF-Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 10 (Reuters) - Vera Therapeutics, Inc VERA.O:VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA4403KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2324357040.USD","BK4539","BK4585","BK4139","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626148699","title":"Vera Therapeutics grants inducement awards to 89 hires, issuing 258,200 options and 131,925 RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2626148699","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626148699?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:30","pubTimestamp":1775853014,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted inducement equity awards to 89 new employees on April 8, 2026 under its 2024 Inducement Plan.Awards included non-qualified stock options covering 258,200 Class A shares.Grants also included RSUs covering 131,925 Class A shares.Stock options carry an exercise price of $40.33 per share.Options vest over four years; RSUs vest over four years starting May 20, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL6VrTKx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014039.USD","BK4585","BK4539","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU2095319765.USD","VERA","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4588","LU2210150020.SGD","LU2324357040.USD","SG9999014013.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626352130","title":"Vera Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626352130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626352130?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:07","pubTimestamp":1775765221,"startTime":"0","endTime":"0","summary":"Vera Therapeutics set annual shareholder meeting for May 21, 2026, to be held via live webcast.Shareholders will vote on election of three Class II directors to serve until 2029 annual meeting.Meeting agenda includes ratification of KPMG as independent registered public accounting firm for fiscal 2026.Advisory vote scheduled on compensation of named executive officers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbMJMTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4585","BK4588","LU2324357040.USD","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870780","title":"Vera Therapeutics grants 56,850 stock options at $40.73; issues 42,403 RSUs under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870780","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870780?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:05","pubTimestamp":1774641918,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted non-qualified stock options covering 56,850 Class A shares and RSUs covering 42,403 Class A shares to new Chief Legal Officer Jane Wright-Mitchell.The stock options have an exercise price of USD 40.73 per share and vest over four years.25% of the stock option shares vest on the first anniversary of the vesting start date, with the remainder vesting monthly over 36 months.The RSUs vest over four years, with 25% vesting on each anniversary of May 20, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL545qF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","SG9999014021.USD","BK4585","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","LU2324357040.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","BK4139","BK4539","BK4588","VERA","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808757","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808757?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:05","pubTimestamp":1774641900,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/27/3264085/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","BK4539","BK4139","VERA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078867","title":"Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078867","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078867?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:30","pubTimestamp":1774438229,"startTime":"0","endTime":"0","summary":"Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately.Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies.Her prior roles include General Counsel, Chief Compliance Officer and Corporate Secretary at Vaxcyte, and Chief Legal Officer positions at other pharmaceutical and research companies.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL5FDKSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NDAQ","LU2210150020.SGD","LU2324357040.USD","BK4585","LU0053671581.USD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","PCVX","IE00BKPKM429.USD","VERA","LU2210149790.SGD","IE00BN0W2W23.USD","BK4588","IE00BGHQF748.EUR","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00B64PRP62.GBP","BK4539","IE0009354923.USD","LU0314104364.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620342250","title":"Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342250?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750629,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cochlear (CHEOF – Research Report), Universal Heal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XLV","UHS","BK4581","LU0128526141.USD","LABU","XBI","BK4585","BK4137","BK4139","BK4539","HCSG","VERA","BK4185","LU2324357040.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619464244","title":"Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464244","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464244?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:10","pubTimestamp":1773666627,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.\nSee our latest analysis for Vera Therapeutics.\nAt a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","DCF","BK4588","BK4539","LU2324357040.USD","BK4139","BK4585","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618944664","title":"Vera Therapeutics Raised to Outperform From Peer Perform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944664?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:55","pubTimestamp":1773230100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 07:55 ET (11:55 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618967707","title":"Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618967707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618967707?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:05","pubTimestamp":1773183913,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Andy Chen upgraded Vera Therapeutics (VERA) to Outperform from Peer Perform with an $88 price target. Vertex’s (VRTX) report...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618778496","title":"Vera Therapeutics appoints Christopher Hite to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618778496","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618778496?lang=en_us&edition=fundamental","pubTime":"2026-03-10 05:02","pubTimestamp":1773090156,"startTime":"0","endTime":"0","summary":"Vera Therapeutics appointed Christopher Hite to its board, effective immediately. Hite will serve as a Class III director with a term expiring at the 2027 annual meeting of stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLcbQvVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","BK4539","VERA","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617702630","title":"Vera Therapeutics Grants Inducement Stock Options and RSUs to Six New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2617702630","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617702630?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:05","pubTimestamp":1772831115,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted inducement awards to six new employees under its 2024 Inducement Plan, consisting of non-qualified stock options for 46,000 Class A shares and RSUs covering 25,875 Class A shares. The options have an exercise price of $39.30 per share and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The RSUs also vest over four years, with 25% vesting on each anniversary of either February 20 or May 20, 2026, depending on the employee’s start date.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDLc275ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","VERA","IE00B3QW5Z07.USD","BK4585","BK4112","LU2324357040.USD","NDAQ","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","LU2210150020.SGD","BK4539","LU2095319765.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617658592","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658592?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:05","pubTimestamp":1772831100,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  06, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/06/3251308/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2324357040.USD","BK4539","BK4588","VERA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617523074","title":"Vera Therapeutics appoints Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523074","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523074?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:16","pubTimestamp":1772720191,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) announced the appointment of Christopher Hite to Vera Therapeutics’ Board of Directors. Published first on TheFly – the ul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","VERA","BK4139","BK4539","BK4588","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617523822","title":"Vera Therapeutics Appoints Christopher Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523822","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523822?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719200,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  05, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250276/0/en/Vera-Therapeutics-Appoints-Christopher-Hite-to-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VERA","BK4588","BK4585","LU2324357040.USD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332316","title":"Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332316?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:53","pubTimestamp":1772455980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:53 ET (12:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616770339","title":"Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616770339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616770339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:57","pubTimestamp":1772452658,"startTime":"0","endTime":"0","summary":"In a report released today, Dina Ramadane from Bank of America Securities reiterated a Buy rating on Vera Therapeutics, with a price target of $66....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616335065","title":"Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335065?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:11","pubTimestamp":1772449901,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a Buy rating on the shares. The firm updated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614816513","title":"Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614816513","media":"Simply Wall St.","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614816513?lang=en_us&edition=fundamental","pubTime":"2026-02-28 17:30","pubTimestamp":1772271010,"startTime":"0","endTime":"0","summary":"Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date.\nAlongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4139","BK4539","VERA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.0774},{"period":"1month","weight":0.0849},{"period":"3month","weight":-0.0611},{"period":"6month","weight":0.3913},{"period":"1year","weight":1.0125},{"period":"ytd","weight":-0.142}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.047765},{"month":4,"riseRate":0.2,"avgChangeRate":-0.064471},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction